Add a New Bulls Reason

Company: CVS Caremark Corporation (CVS)
Current price:
Headline: (100 character max)
Analysis:
Cancel
87%
agree
16 votes

  Medicare part D

Favorable government policy such as Medicare Part D will drive increased drug sales for both prescriptions and generics. This favors CVS's future revenue outlook.

CVS: Buy = $23; Target = $46; Consensus P/E = 16.3

Due to the below regulation and other government 'plans' a cautious entry price is advised.

CVS 10-Q, June 30, 2009, p.25: "In January 2009, the Centers for Medicare and Medicaid Services issued a regulation requiring that, beginning in 2010, any difference between the drug price charged to Medicare Part D plan sponsors by a PBM and the drug price paid by the PBM to the dispensing provider (commonly called “differential” or “spread”) be reported as an administrative cost rather than a drug cost of the plan sponsor for purposes of calculating certain government subsidy payments and the drug price to be charged to enrollees. These changes impact our ability to offer Medicare Part D plan sponsors pricing for 2010 that includes the use of retail network “differential” or “spread,” and we expect these changes to reduce the profitability of our Medicare Part D business beginning in 2010."

(100 character max) Cancel
66%
agree
3 votes

  Good at increasing Same Store Sales in acquired stores

Remodels of newly acquired Eckerd, Osco, and Sav-on stores will drive revenue and operating margins.

(100 character max) Cancel
50%
agree
2 votes

  Recession moves customers towards CVS generics

CVS's Q4 2008 profits increased 17%, largely on customers buying more generic goods. CVS-brand goods, which are cheaper than name brand competing products, have higher profit margins for the company. As the recession continues, the company stands to benefit from more movement towards generic CVS brand sales.

(100 character max) Cancel
50%
agree
2 votes

  Purchasing power means higher margins on meds

Unrivaled economies of scale and purchasing power of the combined company will drive lower prescription prices and higher operating margins.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki